Septo-optic dysplasia and growth hormone deficiency: accelerated pubertal maturation during GH therapy.
We report four patients (three male, one female) with septo-optic dysplasia and growth hormone deficiency. All had GH therapy for a period of four to eight years until reaching final height. In all four cases bone maturation during puberty was accelerated (1.4 to 1.9 "years"/year), resulting in a final height which was clearly below the predicted height. The progress of pubertal stages was very short in all patients. In three patients TSH and prolactin release after TRH stimulation were increased. These data support a hypothalamic original of the endocrine disorder. Insufficient GH release, even after repeated GHRH stimulation, is in contrast to this assumption. In one case there was a late manifestation of neurohormonal diabetes insipidus, which indicates the possibility of later disease progression. MR imaging of the brain demonstrated variable malformation of the septum pellucidum, chiasma and nervus opticus or the pituitary gland, respectively.
Freude
S
S
Department of Paediatrics, University Hospital, Vienna, Austria.
Frisch
H
H
Wimberger
D
D
Schober
E
E
Hüsler
G
G
Waldhauser
F
F
Aichner
F
F
D000015:Abnormalities, Multiple / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D002648:Child; D002675:Child, Preschool; D005260:Female; D006128:Growth; D006130:Growth Disorders / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D013006:Growth Hormone / Q000172:deficiency* / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D008297:Male; D009900:Optic Nerve / Q000002:abnormalities*; D010907:Pituitary Hormones / Q000097:blood; D012688:Septum Pellucidum / Q000002:abnormalities*; D013577:Syndrome; D013963:Thyroid Hormones / Q000097:blood
D010907:Pituitary Hormones; D013963:Thyroid Hormones; D013006:Growth Hormone